Wall Street Zen upgraded shares of Harrow (NASDAQ:HROW – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.
Several other equities analysts have also recently weighed in on HROW. Zacks Research cut Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 11th. Cantor Fitzgerald dropped their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. BTIG Research reissued a “buy” rating and issued a $63.00 price target on shares of Harrow in a research report on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Monday, July 20th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $69.43.
Check Out Our Latest Stock Analysis on HROW
Harrow Stock Performance
Harrow (NASDAQ:HROW – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The business had revenue of $70.66 million for the quarter, compared to analyst estimates of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%. On average, sell-side analysts anticipate that Harrow will post 0.11 EPS for the current fiscal year.
Insider Activity
In other news, Director Adrienne L. Graves acquired 1,000 shares of Harrow stock in a transaction that occurred on Monday, May 18th. The stock was purchased at an average price of $31.07 per share, with a total value of $31,070.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at approximately $31,070. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 12.80% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of HROW. Freestone Grove Partners LP purchased a new stake in shares of Harrow during the 2nd quarter worth about $157,000. First Bancorp Inc ME bought a new stake in shares of Harrow in the 2nd quarter valued at approximately $64,000. Jupiter Topco LLC acquired a new position in Harrow in the second quarter worth approximately $24,596,000. Legal & General Group Plc acquired a new position in Harrow in the second quarter worth approximately $1,139,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Harrow in the second quarter worth approximately $600,000. 72.76% of the stock is owned by institutional investors and hedge funds.
Key Harrow News
Here are the key news stories impacting Harrow this week:
- Positive Sentiment: Harrow’s potential acquisition or commercialization of Viatris’ Tyrvaya could create a new growth opportunity if the company can expand the ophthalmic drug’s sales and reach. Viatris Is Selling Tyrvaya, but Could Harrow Turn It Into a Growth Engine?
- Positive Sentiment: A Seeking Alpha analysis characterized Harrow’s second-quarter turnaround as sufficient to support a cautious-buy view, offering a more constructive perspective on the company’s operating trajectory. Harrow: The Q2 Turnaround Is Enough for a Cautious Buy
- Positive Sentiment: BTIG Research reaffirmed its buy rating, signaling continued confidence in Harrow’s longer-term prospects. BTIG Research Reaffirms Buy Rating for Harrow
- Neutral Sentiment: HC Wainwright made a minor increase to its Q4 2027 EPS forecast, to $1.07 from $1.06, indicating limited improvement in one later-period estimate.
- Negative Sentiment: HC Wainwright significantly reduced its earnings forecasts: FY2026 moved to a loss of $0.57 per share from earnings of $0.15, FY2027 fell to $0.88 from $1.14, and Q3 2026 declined to $0.01 from $0.26. Estimates for Q1 and Q2 2027 were also lowered to losses of $0.63 and $0.12 per share, respectively. The revisions contrast with the current full-year consensus estimate of $0.30.
- Negative Sentiment: Zacks Research downgraded Harrow from “hold” to “strong sell,” adding to concerns about valuation and near-term profitability. Zacks.com
- Negative Sentiment: Recent coverage linked a prior gap lower in HROW shares to weak earnings, reinforcing investor concerns about the company’s ongoing losses and execution. Harrow Shares Gap Down Following Weak Earnings
About Harrow
Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.
Featured Stories
- Five stocks we like better than Harrow
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
